J&J's Zytiga Extends Life, Boosts Prostate Drug Market
4,958 views · Published 2 June 2011 · 2:35 · Indexed 14 November 2026
Channel: Bloomberg Originals · 2011 · Entertainment
June 2 (Bloomberg) -- Bloomberg's Shannon Pettypiece reports on Johnson & Johnson's Zytiga, the first prostate cancer pill to win U.S. marketing approval in a family of treatments that offer new ways to stymie the male hormones that fuel tumor growth.
Similar medicines from Medivation Inc. and Takeda Pharmaceutical Co. will report study results this weekend at the American Society of Clinical Oncology meeting in Chicago. Pettypiece speaks with Betty Liu on Bloomberg Television's "In the Loop." (Source: Bloomberg)
More from this channel
-
3:30
Market Close 6.4 - Bloomberg
-
0:17
Pens Tie Stanley Cup Series - Bloomberg
-
0:35
Hardware Price Too High - Activision - Bloomberg
-
0:31
FDIC Seeks Citigroup Shares-Up - WSJ - Bloomberg
-
0:44
Bank Have More Accounting Leeway - Bloomberg
-
0:32
Lakers Beat Magic 100-75 - Bloomberg
-
0:30
Johnson Wins 300th Game - Bloomberg
-
1:13
GM Expects To Sell Saturn To Penske Automotive - Bloomberg